Antibe Therapeutics Announces the Launch of PentOS OI™ Max, Its Newest Bone Graft Substitute for Oral and Maxillofacial Surgery

1 February 2017

Antibe Therapeutics Inc. today announced that its subsidiary Citagenix Inc. (“Citagenix”) has launched PentOS OI™ Max for the dental biologics market.